Shots:

• The approval is based on two P-III studies assessing Taltz vs PBO in 657 patients with active AS- randomized into two groups i.e- COAST-V in patients who are bDMARD-naïve and COAST-W in patients who are intolerant or have an inadequate response to TNF inhibitors
• The two P-III study results: patients achieved ASAS40 @16wks. COAST-V (48% vs 18%)- COAST-W (25% vs 13%); improvement in 2EPs- COAST-V (64% vs 40%)- COAST-W (48% vs 30%); reduction in pain & inflammation
• Taltz is a mAb targeting IL-17A cytokine- inhibiting its interaction with the IL-17 receptor and received its first FDA’s approval in Mar’2016 for mod. to sev. plaque psoriasis and second approval in Dec’2017 for active psoriatic arthritis in adults

Click here to­ read full press release/ article

Ref: Eli Lilly | Image: Eli Lilly